alexa Vaccine Adjuvants and Delivery Technologies
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

Special Issue: Vaccine Adjuvants and Delivery Technologies

A Vaccine adjuvant is an ingredient of a vaccine that helps create a stronger immune response in the patient’s body.  In other words, adjuvants help vaccines work better. Some vaccines made from weakened or dead germs contain naturally occurring adjuvants and help the body produce a strong protective immune response. However, most vaccines developed today include just small components of germs, such as their proteins, rather than the entire virus or bacteria. These vaccines often must be made with adjuvants to ensure the body produces an immune response strong enough to protect the patient from the germ he or she is being vaccinated against. Aluminum gels or aluminum salts are vaccine ingredients that have been used in vaccines since the 1930s.  Small amounts of aluminum are added to help the body build stronger immunity against the germ in the vaccine. Aluminum is one of the most common metals found in nature and is present in air, food, and water. The amount of aluminum present in vaccines is low and is regulated by the U.S. Food and Drug Administration (FDA).

As a part of this special issue researchers and scholars are invited to submit manuscripts on all aspect of vaccines research but not limited to the topics such as New vaccine technology including adjuvants and delivery systems, Next-Generation Adjuvants, Advances in DNA Vaccines, TLRS and Combination Adjuvants, Addressing Unmet Vaccine Needs, DNA delivery technologies, Needle-free vaccine delivery, Nanopatch Technologies, Adjuvants and Delivery systems for prophylactic and therapeutic vaccines,  etc.

The Journal follows a stringent double blind peer review process for all submitted manuscripts. We welcome manuscripts for the special issue till “August 15th, 2017”. The submitted manuscripts would be published by “September 25th, 2017”. As the submission for the special issue would be limited in number & would be processed on a First come First Serve basis.

You may submit your paper by or online at https://www.editorialmanager.com/pharma/ or e-mail at [email protected]



This Special issue is being edited by

Wang Ji

Harvard Medical School
USA
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords